Clinical genome study on the individual differences of infliximab-BS(CTH) subjected to Japanese and Korean rheumatoid arthritis patients at large number of facilities (1) Clinical genome study on the drug responsiveness of Japanese rheumatoid arthritis patients towards infliximab-BS(CTH)

Clinical genome study on the individual differences of infliximab-BS(CTH)subjected to Japanese and Korean rheumatoid arthritis patients at large number of facilities (1)Clinical genome study on the drug responsiveness of Japanese rheumatoid arthritis patients towards infliximab-BS(CTH) - Clinical genome study on the drug responsiveness of Japanese rheumatoid arthritis patients towards infliximab-BS(CTH)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037837

Enrollment

100

Registered

2019-09-01

Start date

2019-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Among the patients who are undergoing treatments as outpatients or hospitalized at the research institutes, 100 patients diagnosed with rheumatoid arthritis and scheduled to be administered with or already being administered with Infliximab-BS(CTH), who were "requested for cooperation with the research on rheumatoid arthritis" by the personnel in charge of the execution of the research or medical doctor at the cooperative institution for the execution of the research and provided documentary consent by using "Letter of consent for cooperation with research on rheumatoid arthritis"(Attachments(1) and (2)) are selected as the subjects of the research.

Exclusion criteria

Exclusion criteria: The patients administered with Infliximab-BS sold by other company is excluded.

Design outcomes

Primary

Measure	Time frame
SNPs that stipulate drug responsiveness to Infliximab-BS [CTH]	—

Secondary

Measure	Time frame
1.Comparison of SNPs that stipulate drug responsiveness to Infliximab-BS(CTH) and original medical drug, infliximab (effectiveness and safety) 2.Infliximab trough value and quantity of anti-drug antibody prior to and after the administration of Infliximab-BS(CTH)	—

Countries

Japan

Contacts

Public ContactKeiko Funahashi

research institute of Joint Disease Vice president

kansetsusaisei123@cup.ocn.ne.jp078-515-6145

Outcome results